Bioventus Reaffirms Adjusted EPS and Updates 2026 Sales Range

The Tip Desk · November 10, 2026 · 3 min read

Third-quarter revenue was $142.4 million as Pain Treatments rose 6.2% and the company kept 2026 Adjusted EPS at $0.75 to $0.79 a share.

Bioventus Inc. (BVS), a global maker of products for active healing, reported third-quarter worldwide revenue of $142.4 million, up 3% from a year earlier, and said it is continuing to review potential strategic alternatives.

The company attributed the sales increase primarily to Pain Treatments. Global Pain Treatments revenue was $71.3 million, up 6.2%, which the company said reflected volume growth in hyaluronic acid therapy led by Durolane, as well as its platelet-rich plasma system and peripheral nerve stimulation products.

Surgical Solutions revenue was $50.5 million, up 0.7%, driven by higher demand in Ultrasonics systems and disposables, partially offset by softness in Bone Graft Substitutes. Restorative Therapies revenue was $20.6 million, down 3.4%, due to lower volume for the EXOGEN Bone Stimulation System.

U.S. net sales were $124.6 million, up 1.0%, on Pain Treatments growth that was partially offset by Bone Graft Substitutes softness. International net sales were $17.8 million, up 16.4%, which the company said was driven by Pain Treatments volume from Durolane and increased Surgical Solutions demand related to Ultrasonics.

Net income attributable to Bioventus Inc. was $6.0 million, compared with $3.2 million in the prior-year period. GAAP earnings were $0.08 a diluted share, versus $0.05 a share a year earlier. Non-GAAP earnings were $0.17 a diluted share, up 13% from $0.15 a share, which the company said was driven by lower interest expense. Adjusted EBITDA was $28.4 million, up 7% from $26.6 million, which the company said reflected higher revenue and disciplined cost management, partially offset by increased investments to fund future growth.

Cash from operations totaled $20.7 million. During the third quarter the company made a discretionary principal prepayment of $15.0 million on its term loan, funded by operating cash flows, and said the reduction in long-term debt lowers future interest payments and borrowing costs with improved financial metrics in its credit agreement.

For the twelve months ending December 31, 2026, Bioventus reaffirmed Adjusted EPS guidance of $0.75 to $0.79 a diluted share. It presented Adjusted Cash from Operations of $84 million to $89 million, which excludes the cash-flow impact of costs related to the review of potential strategic alternatives. It updated Net Sales guidance to $590 million to $595 million, reflecting growth of approximately 4% to 5%. Cash paid in connection with the strategic-alternatives review was $0.4 million during both the three and nine months ended September 26, 2026.

President and Chief Executive Officer Rob Claypoole said the company delivered solid third-quarter results demonstrated by strong gross margin, operating cash flow and Adjusted EBITDA, and that it remains confident in its strategy, portfolio and ability to build Bioventus into a leading medtech company. He also said the company continues to review potential strategic alternatives as it explores opportunities to maximize value for shareholders.